Acadia Pharmaceuticals Inc.
ACAD
Key stats
- Open
- 18.22
- Day high
- 18.37
- Day low
- 17.93
- Previous close
- 18.37
- Volume
- 1.93M
- VWAP
- 18.13
- 52-week high
- 30.96
- 52-week low
- 15.86
- Market cap
- 3.17B
- Shares out
- 172.31M
- Employees
- 798
- Listed
- 2004
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
PHARMACEUTICAL PREPARATIONS · SAN DIEGO, CA · acadia.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 11.6K
- Put open interest
- 9.0K
- Put/call
- 0.77
- At-the-money IV
- 52.1%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 14 call | 5.90 | Oct 16, 12:49 PM | 61 | 61 | 144.9% |
| 21 call | 0.10 | Nov 9, 3:57 PM | 50 | 7.1K | 109.3% |
| 17 put | 0.32 | Nov 11, 1:01 PM | 24 | 142 | 47.5% |
| 21 put | 3.70 | Nov 10, 10:26 AM | 21 | 77 | — |
| 16 put | 0.40 | Nov 10, 10:13 AM | 13 | 17 | 112.6% |
| 15 put | 0.10 | Nov 10, 9:33 AM | 10 | 12 | 114.8% |
Quarterly results
Massive · Nov 5, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $342.29M | $307.96M | $268.06M | $283.99M |
| Gross profit | $307.20M | $279.64M | $243.27M | $257.76M |
| Operating income | $71.72M | $37.84M | −$4.62M | $17.39M |
| Net income | $53.52M | $31.50M | $3.64M | $273.57M |
| Diluted EPS | 0.31 | 0.18 | 0.02 | 1.58 |
| Operating cash flow | $11.50M | $100.78M | $33.98M | −$48.73M |
| Assets | $1.79B | $1.74B | $1.61B | $1.56B |
| Liabilities | $406.66M | $436.29M | $357.16M | $336.81M |
| Equity | $1.39B | $1.31B | $1.25B | $1.23B |
Technicals
Massive · Nov 12, 2026- 50-day average21.97
- 200-day average23.37
- RSI (14 days)37.8
Short interest
Massive · Oct 30, 2026- Oct 30, 20268.32M shares · 5.9 days to cover
- Oct 15, 20269.09M shares · 4.6 days to cover
- Sep 30, 20268.28M shares · 2.9 days to cover
- Sep 15, 20269.67M shares · 7.2 days to cover
News coverage
No stories about Acadia Pharmaceuticals Inc. right now.